Kataoka T
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.
Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 2):445-51.
We examined interferon (IFN)-alpha therapy in animal models from the immunological aspects. Long after the cessation of successful IFN administration there found a strong tumor neutralizing activity of spleen T cells in the curing mice. However, this activity was not detectable right after the cessation of IFN administration. Instead, in this early stage, a strong tumor neutralizing activity was found in the lymph nodes of IFN-administered mice. This does not necessarily indicate that the primary modifying target of IFN was T cells since IFN is not capable of directly activating T cells. Further experimentation showed that IFN administration resulted in the very fast production of antitumor monocytes in peripheral blood. Again, this may not be a primary modifying target of IFN since IFN is a very poor activator of monocytes and macrophages and sometimes a very strong nullifier of activation of these cells. Based on these results and those reported in the literatures, it was discussed what would be a real modifying target of IFN in association with the therapeutic effect.
我们从免疫学角度在动物模型中研究了α干扰素（IFN）疗法。在成功给予IFN后很长时间，在治愈的小鼠中发现脾脏T细胞具有很强的肿瘤中和活性。然而，在停止给予IFN后立即检测不到这种活性。相反，在这个早期阶段，在给予IFN的小鼠的淋巴结中发现了很强的肿瘤中和活性。这不一定表明IFN的主要修饰靶点是T细胞，因为IFN不能直接激活T细胞。进一步的实验表明，给予IFN会导致外周血中抗肿瘤单核细胞的快速产生。同样，这可能不是IFN的主要修饰靶点，因为IFN是单核细胞和巨噬细胞的非常弱的激活剂，有时还是这些细胞激活的非常强的抑制剂。基于这些结果以及文献中报道的结果，讨论了与治疗效果相关的IFN的真正修饰靶点可能是什么。
